Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Innovative Wearable and Open Platform for a Personalized Treatment of Stress

Objetivo

The XANA project aims at developing a user-friendly wearable device and ICT solution for the customized treatment of stress. We will provide an innovative and non-invasive technology of stimulation of the vagus nerve and a range of integrated services such as feedback on performance, monitoring and access to professional counselling when needed.

Stress is suffered by over 26% of working population. The European Commission estimated in 2002 the cost of work-related stress at €20 billion a year just in the EU-15. Of this, direct costs are mostly paid by the public healthcare systems, and indirect costs are related to productivity loss, ultimately impacting national economies.

Current alternatives do not fully solve the challenge of stress treatment, because of their limited efficacy and presence of secondary effects (invasive electrical stimulation or pharmacological treatment). Moreover, the treatment results are very variable, time consuming (psychological techniques) and expensive. XANA main benefits are: avoidance of secondary effects, high efficacy, user-friendliness, fast and customized treatment providing actual physiological activity. XANA will contribute to the development of mobile Health in Europe. In this, the ICT characteristics of the product are key to possibly enabling burden-reduction in healthcare systems through real-time treatment optimisation and remote medical monitoring/counselling.

XANA project is led by the Spanish start-up Walden Medical®. XANA has a clear potential for becoming an international benchmark in the field of mental health. We have estimated that after 5 years from launch, we will build around 69.700 devices (sales €28M), hire 12 technical employees and manage 0.1% of the world market. We will earn around €10M profit and generate a R.O.I of 6.90. Investment in the XANA product will furthermore ease commercialization of Walden Medical® technologies for other high prevalence conditions: anxiety and migraine.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

SME-1 - SME instrument phase 1

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-SMEInst-2016-2017

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

WALDEN MEDICAL NEURO DIGITAL THERAPIES, S.L.
Aportación neta de la UEn
€ 50 000,00
Dirección
C/ LOS PRADOS 166
33203 GIJON
España
Pyme
Sí
Región
Noroeste Principado de Asturias Asturias
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00